Q&A with Greg Irace,sanofi-aventis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Greg Irace,sanofi-aventis
Greg Irace, president of sanofi-aventis, on recent industry trends.

Pharmaceutical Technology
Volume 35, Issue 5, pp. 96

Q&A with
Greg Irace, president of sanofi-aventis


Greg Irace
PharmTech:
What is the biggest industry challenge you're now facing?

Irace:
I'd say the biggest challenge we're all facing is change. From the end of the blockbuster era, to the impact of healthcare reform, to a challenging regulatory environment and the changing dynamics between patients, payors, and providers, the entire context in which we operate is changing.

Globally, sanofi-aventis has taken many steps to stay ahead of the curve and address these challenges. First, we are diversifying our business. We now consider ourselves not just a pharmaceutical company, but a diversified healthcare company. In addition to our pharmaceutical and vaccine businesses, we have built a significant presence in consumer health, animal health, and emerging markets. We are also being more strategic about how we allocate resources; we're now concentrating on high-growth areas, including diabetes, oncology, and atrial fibrillation. Ultimately, we work with our partners to protect health and enhance life. I believe these moves will set us up for long-term sustainable growth.

PharmTech:
Do you see a new industry trend emerging?

Irace:
We are excited about the trend of using a decentralized approach. Companies are forming disease-based units with their own experts dedicated to research and development, regulatory affairs, marketing, and sales. The goal of this approach is to bring the best and brightest minds and methods to bear early on in the development process of a potential treatment and to leverage those resources throughout the product's life cycle.

Recognizing patients' evolving needs and the challenging environment in which we are operating, sanofi-aventis US has adopted a decentralized model. We hope this approach will result in greater efficiencies—improving the likelihood of success by focusing efforts on fewer projects with greater potential—and improved innovation, ultimately benefiting patients.

We're also energized by developments in the medical-device arena that have the potential to change the way patients manage their conditions. sanofi-aventis US offers various devices to simplify insulin use for patients.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here